Search 

Trove is a semi-virtual biotech start-up located in Rockville, Maryland, USA, developing an advanced biologic asset and seeking funding and partners to conduct clinical trials in respiratory disease. We have data and drug supply on our lead, clinical-stage biologic asset to support up to 3 clinical trials in different respiratory conditions (2 x Phase 1b/2a in COVID and lung transplant; and 1 x Phase 2 in chronic sinusitis). Our biologic, called Therabron, is a replacement for a normally abundant native protein that is deficient in our targeted indications. Replacement therapies have a high approval rate with FDA (>70%) and patients with genetic deficiencies can be selected in some trials to increase our chances of demonstrating efficacy. Therabron was safe in 3 early studies. At present, the quickest path to an approval is likely an Emergency Use Authorization in severe COVID-19 patients, so we're looking for an initial $2M seed/Series A round to fund a Phase 1b/2a clinical trial then need another $16M to produce more drug and perform a convincing Phase 2 trial. We are already talking to several potential corporate partners, have signed one CDA with a top 5 pharma, and a relatively small amount of investment in clinical proof of concept demonstrations will attract at least one partner. Once clinical POC is established in targeted indications, we plan to exit via sale/acquisition or out-license. Our markets are large (3 products x >$1B each US) and deal comps in the respiratory space are $250M each and up. We can maximize our ROI by out-licensing the first indication and re-investing upfront license payment proceeds to advance the drug in further indications, depending on what happens in each field/indication and what we (management team and investors) decide to do.

We have, by a wide margin, the safest and most effective nocturia drug. Nocturia leads to over 10,000 deaths per day and costs the US economy $215B/year in lost worktime and lower productivity.

Whale Bay & Co is a boutique financing firm focused solely on the life sciences industry. Based in Rotterdam (the Netherlands) and Basel (Switzerland) we serve SME's, investors and mid-size strategic companies in Biotech, Pharma, MedTech and Digital Health in the strategy and financial space: licensing, financing, M&A, valuation and outsources BD. We have a keen interest to expand our network and business into China. In the context of specific mandates we would like to connect with:

- pharma & medtech companies for outlicensing/JV collaborations with our clients
- investors looking for early and late stage pharma, biotech and medtech investment opportunities
- (FoF)investors interested in investment in funds

Eudendron is an Italian biotech company founded by Dr. Mauro Angiolini and Dr. Fabio Zuccotto. Eudendron develops anti-cancer agents for applications within the precision medicine model, adopting a tumor agnostic approach and targeting populations of patients hosting genetically defined cancers. Purpose of the company is to advance novel cancer treatments from their inception to Phase I/II. The activities of the company are also focused on the identification of novel drugs effective against protein kinase mutations responsible for clinical drug resistance. Eudendron discovered and patented a new class of highly specific inhibitors with excellent anti-cancer properties against several types of cancer cells. Patents in Europe and in USA have already been granted covering inhibitors of relevant oncology targets and their mutations. Lung and thyroid cancer, lymphoma, neuroblastoma and cutaneous cancer are diseases with unmet medical need of particular interest. Especially for neuroblastoma, the company identified drugs with a potent and specific profile. Eudendron is committed to identify Investors and/or industrial Partners to advance the pipeline programs toward the clinical stage. Basket trials will be finally designed following an agnostic clinical development.

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in 2021. Additional products are in encapsulation feasibility studies including targeting dry eye disease and other solid tumors. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. The key platform patent was awarded by USPTO in 2019. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 18 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.